Hum. Reprod. Advance Access originally published online on September 30, 2005
Human Reproduction 2006 21(1):80-89; doi:10.1093/humrep/dei311
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Combined lifestyle modification and metformin in obese patients with polycystic ovary syndrome. A randomized, placebo-controlled, double-blind multicentre study
1 Department of Reproductive Medicine, Clarendon Wing, The General Infirmary, Leeds LS2 9NS, UK 2 Department of Reproductive Medicine, St Marys Hospital, London W2 and 3 Department of Clinical Biochemistry, The General Infirmary, Leeds LS1 3EX, UK
4 To whom correspondence should be addressed. E-mail: Adam.balen{at}leedsth.nhs.uk
BACKGROUND: It has been reported that women with polycystic ovary syndrome (PCOS) benefit from metformin therapy. METHODS: A randomized, placebo-controlled, double-blind study of obese (body mass index >30 kg/m2), oligo-/amenorrhoeic women with PCOS. Metformin (850 mg) twice daily was compared with placebo over 6 months. All received the same advice from a dietitian. The primary outcome measures were: (i) change in menstrual cycle; (ii) change in arthropometric measurements; and (iii) changes in the endocrine parameters, insulin sensitivity and lipid profile. RESULTS: A total of 143 subjects was randomized [metformin (MET) = 69; placebo (PL) = 74]. Both groups showed significant improvements in menstrual frequency [median increase (MET = 1, P < 0.001; PL = 1, P < 0.001)] and weight loss [mean (kg) (MET = 2.84; P < 0.001 and PL = 1.46; P = 0.011)]. However, there were no significant differences between the groups. Logistic regression analysis was used to analyse the independent variables (metformin, percentage of weight loss, initial BMI and age) in order to predict the improvement of menses. Only the percentage weight loss correlated with an improvement in menses (regression coefficient = 0.199, P = 0.047, odds ratio = 1.126, 95% CI 1.001, 1.266). There were no significant changes in insulin sensitivity or lipid profiles in either of the groups. Those who received metformin achieved a significant reduction in waist circumference and free androgen index. CONCLUSIONS: Metformin does not improve weight loss or menstrual frequency in obese patients with PCOS. Weight loss alone through lifestyle changes improves menstrual frequency.
Key words: menstrual frequency/metformin/obese/polycystic ovary syndrome/weight loss
![]()
CiteULike
Connotea
Del.icio.us What's this?
This article has been cited by other articles:
![]() |
D. L. Rofey, E. M. Szigethy, R. B. Noll, R. E. Dahl, E. lobst, and S. A. Arslanian Cognitive-Behavioral Therapy for Physical and Emotional Disturbances in Adolescents with Polycystic Ovary Syndrome: A Pilot Study J. Pediatr. Psychol., June 21, 2008; (2008) jsn057v2. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Jensterle, A. Janez, B. Mlinar, J. Marc, J. Prezelj, and M. Pfeifer Impact of metformin and rosiglitazone treatment on glucose transporter 4 mRNA expression in women with polycystic ovary syndrome. Eur. J. Endocrinol., June 1, 2008; 158(6): 793 - 801. [Abstract] [Full Text] [PDF] |
||||
![]() |
The Thessaloniki ESHRE/ASRM-Sponsored PCOS Consens Consensus on infertility treatment related to polycystic ovary syndrome Hum. Reprod., March 1, 2008; 23(3): 462 - 477. [Abstract] [Full Text] [PDF] |
||||
![]() |
E. Moll, F. van der Veen, and M. van Wely The role of metformin in polycystic ovary syndrome: a systematic review Hum. Reprod. Update, November 1, 2007; 13(6): 527 - 537. [Abstract] [Full Text] [PDF] |
||||
![]() |
B. Trolle, A. Flyvbjerg, U. Kesmodel, and F.F. Lauszus Efficacy of metformin in obese and non-obese women with polycystic ovary syndrome: a randomized, double-blinded, placebo-controlled cross-over trial Hum. Reprod., November 1, 2007; 22(11): 2967 - 2973. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. H Balen and A. J Rutherford Managing anovulatory infertility and polycystic ovary syndrome BMJ, September 29, 2007; 335(7621): 663 - 666. [Full Text] [PDF] |
||||
![]() |
F. Orio, F. Manguso, S. Di Biase, A. Falbo, F. Giallauria, D. Labella, A. Tolino, G. Lombardi, A. Colao, and S. Palomba Metformin administration improves leukocyte count in women with polycystic ovary syndrome: a 6-month prospective study Eur. J. Endocrinol., July 1, 2007; 157(1): 69 - 73. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. M. Nelson and R. F. Fleming The preconceptual contraception paradigm: obesity and infertility Hum. Reprod., April 1, 2007; 22(4): 912 - 915. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. S. Legro A 27-Year-Old Woman With a Diagnosis of Polycystic Ovary Syndrome JAMA, February 7, 2007; 297(5): 509 - 519. [Abstract] [Full Text] [PDF] |
||||
![]() |
E. Elia, V. Sander, C.G. Luchetti, M.E. Solano, G. Di Girolamo, C. Gonzalez, and A.B. Motta The mechanisms involved in the action of metformin in regulating ovarian function in hyperandrogenized mice Mol. Hum. Reprod., August 1, 2006; 12(8): 475 - 481. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. Tang, J. Glanville, N. Orsi, J. H. Barth, and A. H. Balen The use of metformin for women with PCOS undergoing IVF treatment Hum. Reprod., June 1, 2006; 21(6): 1416 - 1425. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. H Balen, M. Dresner, E. M Scott, and J. O Drife Should obese women with polycystic ovary syndrome receive treatment for infertility? BMJ, February 25, 2006; 332(7539): 434 - 435. [Full Text] [PDF] |
||||






